ArticleJournal of the American Heart Association2025

Increased Cardiovascular Risk With Lorlatinib in Patients With ALK-Mutated Lung Cancer: A Real-World Comparative Study.

Chien-Yu Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.